UBS Group Begins Coverage on Medline (NASDAQ:MDLN)

Equities research analysts at UBS Group assumed coverage on shares of Medline (NASDAQ:MDLN) in a report released on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $48.00 price target on the stock. UBS Group’s target price points to a potential upside of 11.19% from the company’s previous close.

MDLN has been the topic of several other reports. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medline in a report on Monday. They issued a “hold” rating and a $40.00 target price on the stock. BNP Paribas began coverage on Medline in a report on Monday. They issued a “neutral” rating and a $38.00 price target for the company. Rothschild & Co Redburn began coverage on Medline in a research report on Monday. They set a “neutral” rating and a $42.00 price target on the stock. Wells Fargo & Company started coverage on Medline in a report on Monday. They set an “equal weight” rating and a $42.00 price objective on the stock. Finally, Barclays initiated coverage on shares of Medline in a report on Monday. They set an “overweight” rating and a $50.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Medline has a consensus rating of “Moderate Buy” and an average price target of $46.70.

Medline Stock Up 0.7%

Shares of MDLN stock traded up $0.32 on Monday, reaching $43.17. The company had a trading volume of 655,403 shares, compared to its average volume of 4,944,748. Medline has a 12 month low of $34.89 and a 12 month high of $45.50.

Insider Activity at Medline

In related news, Director Charles N. Mills purchased 2,579,310 shares of the stock in a transaction on Thursday, December 18th. The shares were purchased at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the transaction, the director directly owned 2,441,379 shares of the company’s stock, valued at $70,799,991. This trade represents a -1,870.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Andrew J. Mills acquired 2,586,206 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $29.00 per share, with a total value of $74,999,974.00. Following the acquisition, the director owned 2,586,206 shares in the company, valued at $74,999,974. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Multiple Wall Street firms have initiated coverage with bullish ratings and above‑market price targets (examples include Truist $52, Evercore/BTIG $50, Goldman Sachs $49 and Sanford Bernstein outperform), signaling strong analyst conviction in Medline’s growth story and supporting upside. Analysts Say Medline Has The Secret Sauce For Sustained Growth
• Positive Sentiment: Major brokerage houses and research teams have broadly initiated coverage (Deutsche Bank, JPMorgan, Jefferies, Wells Fargo, Citigroup, Barclays, TD Cowen, Wolfe Research, Mizuho, Rothschild/Redburn and others), which increases visibility and liquidity for MDLN stock and often supports higher trading interest. Medline Coverage Initiated at Deutsche Bank
• Positive Sentiment: Medline’s IPO and market debut were sizable — the company raised roughly $7 billion and saw strong early market interest, which underpins many analysts’ bullish forecasts tied to its product portfolio and scale. IPO/market debut coverage
• Neutral Sentiment: Coverage/press pieces are discussing valuation and whether MDLN is fairly priced after early stability; these analyses add context but don’t change near‑term fundamentals. Is Medline Fairly Priced
• Neutral Sentiment: Some articles in news streams appear mis‑tagged (e.g., a MarketBeat IPO piece focused on Aktis Oncology was associated with MDLN); exercise caution when treating aggregated headlines as firm‑specific signals. A Fresh IPO That Long-Term Investors Shouldn’t Ignore
• Neutral Sentiment: Reported short‑interest data for January appears inconsistent/insignificant (effectively 0 days on available figures), so short pressure is not a current driver based on those numbers.
• Negative Sentiment: A few firms issued neutral/hold recommendations (e.g., BNP Paribas, Rothschild Redb with hold ratings), which could limit upside momentum compared with the many buy/strong‑buy calls. Analyst notes (Zacks)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.